成都圣诺生物科技股份有限公司关于持股5%以上股东及部分董事、高级管理人员减持股份结果公告

Core Viewpoint - The announcement details the results of the share reduction by major shareholders and certain directors and senior management of Chengdu Saintno Biological Technology Co., Ltd, indicating a significant decrease in their holdings [1]. Group 1: Shareholding Information - The major shareholder, Sichuan Development Securities Investment Fund Management Co., Ltd, held 11,407,021 shares, accounting for 7.2478% of the total share capital before the reduction, with 431,021 shares acquired through centralized bidding and 10,976,000 shares through agreement transfer [2]. - Vice General Manager Lu Changliang holds 386,316 shares (0.2455% of total share capital), while Director and Vice General Manager Wang Xiaoli holds 2,298,786 shares (1.4606% of total share capital) [2]. Group 2: Reduction Plan Implementation Results - The reduction plan was disclosed on August 23, 2025, with subsequent announcements regarding share reductions occurring between September 15 and December 10, 2025 [3][4]. - Sichuan Development Securities reduced its holdings by 4,025,841 shares (2.5579% of total share capital) through centralized bidding and block trading, while Lu Changliang and Wang Xiaoli reduced their holdings by 96,575 shares (0.0614%) and 211,640 shares (0.1345%), respectively [4]. Group 3: Compliance and Conclusion - The reduction was completed within the disclosed time frame, and all actions were in compliance with relevant laws and regulations [7][8]. - The actual reductions met the previously disclosed plans, with no violations of commitments noted [7].